BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5

• Press Releases

  Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

  September 5, 2025

   · 

  6 min read
• Press Releases

  Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression

  September 5, 2025

   · 

  3 min read
• Press Releases

  Lactiga Wins NIH Backing for First-in-Class Breastmilk-Derived Antibody in Inflammatory Bowel Disease

  September 5, 2025

   · 

  2 min read
• Press Releases

  Valitor Presents New Preclinical Data Demonstrating VLTR-559, an Anti-VEGF Drug Candidate for Wet AMD with a Twice-Yearly “Treat-and-Release” Regimen, Exhibits Favorable Safety Profile Similar to Short-Acting Anti-VEGFs

  September 5, 2025

   · 

  4 min read
• Press Releases

  Daxor’s Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

  September 5, 2025

   · 

  5 min read
• Press Releases

  Ashvattha Therapeutics Announces Positive Topline 40-Week Phase 2 Results for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

  September 5, 2025

   · 

  5 min read
• Press Releases

  Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference

  September 5, 2025

   · 

  4 min read
• Press Releases

  Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

  September 5, 2025

   · 

  6 min read
• Press Releases

  Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at EURETINA 2025

  September 5, 2025

   · 

  5 min read
• Press Releases

  MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

  September 5, 2025

   · 

  7 min read